Compare XPEL & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEL | OGN |
|---|---|---|
| Founded | 1999 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2019 | 2020 |
| Metric | XPEL | OGN |
|---|---|---|
| Price | $41.49 | $13.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $56.00 | $11.40 |
| AVG Volume (30 Days) | 195.4K | ★ 13.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 12.12 | N/A |
| EPS | 0.37 | ★ 0.55 |
| Revenue | $476,200,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $12.64 | $0.45 |
| Revenue Next Year | $11.98 | $1.67 |
| P/E Ratio | $114.86 | ★ $24.30 |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $31.26 | $5.69 |
| 52 Week High | $55.91 | $13.44 |
| Indicator | XPEL | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 77.63 |
| Support Level | $35.79 | $10.05 |
| Resistance Level | $54.81 | $13.44 |
| Average True Range (ATR) | 2.49 | 0.09 |
| MACD | -0.68 | -0.13 |
| Stochastic Oscillator | 12.94 | 80.77 |
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.